CN114302883A - Vmat2抑制剂及其制备方法和应用 - Google Patents

Vmat2抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN114302883A
CN114302883A CN202080052104.0A CN202080052104A CN114302883A CN 114302883 A CN114302883 A CN 114302883A CN 202080052104 A CN202080052104 A CN 202080052104A CN 114302883 A CN114302883 A CN 114302883A
Authority
CN
China
Prior art keywords
compound
substituted
compound according
added
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080052104.0A
Other languages
English (en)
Other versions
CN114302883B (zh
Inventor
田京伟
张睿
叶亮
于大伟
杜广营
刘宗亮
邹方霞
崔博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Luye Pharmaceutical Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Priority to CN202210968124.3A priority Critical patent/CN115260186B/zh
Publication of CN114302883A publication Critical patent/CN114302883A/zh
Application granted granted Critical
Publication of CN114302883B publication Critical patent/CN114302883B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一类作为VMAT2抑制剂的化合物，具体涉及式(I)所述的化合物或其立体异构体或其药学上可接受的盐及其制备方法，以及在制备治疗与VMAT2相关疾病的药物的应用。
Figure DDA0003475923700000011

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202080052104.0A 2019-08-12 2020-08-11 Vmat2抑制剂及其制备方法和应用 Active CN114302883B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210968124.3A CN115260186B (zh) 2019-08-12 2020-08-11 Vmat2抑制剂及其制备方法和应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019107398455 2019-08-12
CN201910739845 2019-08-12
CN2019110940849 2019-11-11
CN201911094084 2019-11-11
PCT/CN2020/108314 WO2021027792A1 (zh) 2019-08-12 2020-08-11 Vmat2抑制剂及其制备方法和应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210968124.3A Division CN115260186B (zh) 2019-08-12 2020-08-11 Vmat2抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114302883A true CN114302883A (zh) 2022-04-08
CN114302883B CN114302883B (zh) 2022-09-06

Family

ID=74570226

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052104.0A Active CN114302883B (zh) 2019-08-12 2020-08-11 Vmat2抑制剂及其制备方法和应用

Country Status (9)

Country Link
US (1) US20220340562A1 (zh)
EP (1) EP4015517A4 (zh)
JP (1) JP2022547390A (zh)
KR (1) KR20220035204A (zh)
CN (1) CN114302883B (zh)
AU (1) AU2020327501A1 (zh)
BR (1) BR112022002107A2 (zh)
CA (1) CA3148302A1 (zh)
WO (1) WO2021027792A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260186A (zh) * 2019-08-12 2022-11-01 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用
CN115260186B (zh) * 2019-08-12 2024-05-28 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125188A1 (es) * 2021-03-22 2023-06-21 Neurocrine Biosciences Inc Inhibidores del vmat2 y métodos de uso
WO2024064178A1 (en) * 2022-09-21 2024-03-28 Neurocrine Biosciences, Inc. Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484190A (zh) * 2006-05-02 2009-07-15 宾夕法尼亚大学理事会 放射性标记的二氢丁苯那嗪衍生物及其作为显像剂的用途
WO2010026436A2 (en) * 2008-09-08 2010-03-11 Biovail Laboratories International (Barbados) Srl Pharmaceutical compounds
CN102120742A (zh) * 2010-01-08 2011-07-13 中国药科大学 1,3,4,6,7,11b-六氢-9,10-二甲氧基-3-(2-甲基丙基)-2H-苯并[a]喹嗪-2-酮的制备方法
WO2018222549A1 (en) * 2017-05-31 2018-12-06 Five Eleven Pharma Inc. Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
EP3733666B1 (en) * 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484190A (zh) * 2006-05-02 2009-07-15 宾夕法尼亚大学理事会 放射性标记的二氢丁苯那嗪衍生物及其作为显像剂的用途
WO2010026436A2 (en) * 2008-09-08 2010-03-11 Biovail Laboratories International (Barbados) Srl Pharmaceutical compounds
CN102120742A (zh) * 2010-01-08 2011-07-13 中国药科大学 1,3,4,6,7,11b-六氢-9,10-二甲氧基-3-(2-甲基丙基)-2H-苯并[a]喹嗪-2-酮的制备方法
WO2018222549A1 (en) * 2017-05-31 2018-12-06 Five Eleven Pharma Inc. Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BITE PAL 等: "Synthesis of new benzo[a]quinolizine derivatives. I", 《MAGYAR KEMIAI FOLYOIRAT》, vol. 75, no. 1, 31 December 1969 (1969-12-31), pages 3 *
CHEMICAL ABSTRACTS SERVICE RN:956903-28-9: "《STN Registry 数据库》", 6 December 2007, pages: 956903 - 28 *
HANK F. KUNG 等: "In vivo imaging of VMAT2 in pancreas using a 18F epoxide derivative of tetrabenazine", 《NUCLEAR MEDICINE AND BIOLOGY》, vol. 35, no. 8, 30 November 2018 (2018-11-30), pages 825 - 837, XP025678986, DOI: 10.1016/j.nucmedbio.2008.08.004 *
LIN ZHU 等: "An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2", 《NUCLEAR MEDICINE AND BIOLOGY》, vol. 37, no. 2, 28 February 2010 (2010-02-28), pages 133 - 141 *
RAJESH GOSWAMI 等: "Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters", 《NUCLEAR MEDICINE AND BIOLOGY》, vol. 33, no. 6, 31 August 2006 (2006-08-31), pages 685 - 694, XP002513805, DOI: 10.1016/J.NUCMEDBIO.2006.05.006 *
XUESHI HAO 等: "Pancreas-Specific Delivery of b-Cell Proliferating Small Molecules", 《CHEMMEDCHEM》, vol. 11, no. 11, 20 April 2016 (2016-04-20), pages 1129 - 1132, XP055780343, DOI: 10.1002/cmdc.201600116 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260186A (zh) * 2019-08-12 2022-11-01 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用
CN115260186B (zh) * 2019-08-12 2024-05-28 山东绿叶制药有限公司 Vmat2抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
BR112022002107A2 (pt) 2022-04-12
CN115260186A (zh) 2022-11-01
CA3148302A1 (en) 2021-02-18
EP4015517A4 (en) 2023-10-18
WO2021027792A1 (zh) 2021-02-18
JP2022547390A (ja) 2022-11-14
EP4015517A1 (en) 2022-06-22
CN114302883B (zh) 2022-09-06
KR20220035204A (ko) 2022-03-21
US20220340562A1 (en) 2022-10-27
AU2020327501A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
CN114302883B (zh) Vmat2抑制剂及其制备方法和应用
UA118369C2 (uk) Сполуки, що інгібують активність lrrk2 кінази
TW201938556A (zh) 化合物及它們在治療癌症中之用途
CN113260619A (zh) 雷帕霉素衍生物
US9051301B2 (en) Crystalline form of a drug
AU2022283638A1 (en) Co-crystal forms of a novobiocin analog and proline
CN108137608B (zh) Janus激酶1选择性抑制剂及其药物用途
EP3590944A1 (en) Azetidine derivative
EP3858816A1 (en) Novel method for preparing (-)-cibenzoline succinate
CN114364685A (zh) 含氮杂环类化合物，及其制备方法、药物组合物和应用
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
CN115260186B (zh) Vmat2抑制剂及其制备方法和应用
CN115772159A (zh) Kif18a抑制剂
RU2284328C2 (ru) Кристаллы производных таксана и способ их получения
WO2021226020A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
WO2022237875A1 (zh) 含有亚磺酰亚胺基的atr抑制剂化合物
EP4342897A1 (en) Pharmaceutically acceptable salt of pyrazoloheteroaryl derivative and crystal form thereof
WO2023249989A1 (en) Solid forms of deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4146621A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
EP4349829A1 (en) Compound used as bcr-abl inhibitor
EP2797898B9 (fr) Derives piperazinyles pour le traitement de cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant